Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
1.350
+0.010 (0.75%)
At close: Apr 28, 2026, 4:00 PM EDT
1.440
+0.090 (6.67%)
After-hours: Apr 28, 2026, 7:56 PM EDT
Dogwood Therapeutics Employees
Dogwood Therapeutics had 8 employees as of December 31, 2025. The number of employees decreased by 4 or -33.33% compared to the previous year.
Employees
8
Change (1Y)
-4
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$4,439,254
Market Cap
45.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Xilio Therapeutics | 76 |
| Mereo BioPharma Group | 39 |
| Plus Therapeutics | 28 |
| Atossa Therapeutics | 16 |
| Rallybio | 14 |
| Nutriband | 13 |
| Rein Therapeutics | 10 |
| Hyperion DeFi | 9 |
DWTX News
- 5 days ago - Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M - GlobeNewsWire
- 13 days ago - Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy - GlobeNewsWire
- 5 weeks ago - Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 3 months ago - Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 - GlobeNewsWire
- 3 months ago - Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development - GlobeNewsWire
- 4 months ago - Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain - GlobeNewsWire
- 5 months ago - Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 - Accesswire
- 5 months ago - Dogwood Therapeutics Transcript: EGM 2025 - Transcripts